Rx-360 formed to ensure patient safety by enhancing quality and authenticity
Pharma and biotechnology companies and their suppliers have been invited to join a new international not-for-profit organisation called Rx-360.
Pharma and biotechnology companies and their suppliers have been invited to join a new international not-for-profit organisation called Rx-360.
The consortium will be comprised primarily of proprietary and generic drug product manufacturers and their suppliers of ingredients and components.
The organisation has been formed to support an industry-wide commitment to ensuring patient safety by enhancing quality and authenticity throughout the supply chain.
The first meeting will be held on 5 June at the Ronald Reagan Building and International Trade Centre in Washington, DC, US.
"By building this consortium and bringing together leaders from the pharmaceutical and biotechnology industries, our suppliers and regulatory agencies, we can begin to address more directly and swiftly issues critical to a safe and successful supply chain," said Martin VanTrieste, member of Rx-360's advisory committee and Amgen's vice president of quality and commercial operations.
"Rx-360's mission is simple - improve the quality, authenticity and security of the global supply chain so that all patients benefit," he added.
The consortium will develop operating standards, technologies, share data and create a supplier audit sharing function to improve the efficiency, oversight and accountability of the global pharmaceutical supply chain.
Rx-360
info@rx-360.org